Celltrion's 'Rekkirona' Obtains Emergency Use Authorization in Indonesia

Incheon Songdo Celltrion Plant 2 Overview. / Incheon - Photo by Kim Hyunmin kimhyun81@

[Asia Economy Reporter Lee Chun-hee] Celltrion's COVID-19 antibody treatment 'Rekkirona' (generic name Regdanvimab) has received Emergency Use Authorization (EUA) in Indonesia.

Celltrion announced on the 20th that on the 17th, Rekkirona obtained emergency use approval from Indonesia's Food and Drug Authority (BPOM). The EUA applies to adult high-risk patients with mild to moderate COVID-19 confirmed cases.

According to the real-time COVID-19 statistics site Worldometer, as of the 19th, the cumulative number of confirmed COVID-19 cases in Indonesia is 2.88 million, with 73,600 deaths. In particular, the Delta variant (Indian variant) is rapidly spreading, causing a swift increase in confirmed COVID-19 cases.

Celltrion expects that Rekkirona will greatly help prevent the spread of COVID-19 in Indonesia, as recent animal experiments have confirmed Rekkirona's neutralizing ability against the Delta variant virus.

A Celltrion official stated, “We proved the efficacy through global clinical and quality data of Rekkirona, which led to obtaining emergency use approval from Indonesia's Food and Drug Authority. We expect this to accelerate export negotiations for Rekkirona and will do our best to ensure rapid global supply.”

This content was produced with the assistance of AI translation services.